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Introduction
The discovery of RNA interference (RNAi) enabled targeted 
functional screens to investigate new gene functions and 
pathways. In RNAi, a double-stranded RNA molecule is intro-
duced into the cells, which then triggers suppression of gene 
expression at the mRNA level. Techniques used to mediate 
RNAi effects include small interfering RNA (siRNA), short 
hairpin RNA, and microRNA—all these modulators of gene 
expression are among the noncoding RNAs constituting 98% 
of the entire transcriptome.1
Endogenous encoded microRNAs are ~22 nucleotides 
long and regulate more than two-third of genome by cleav-
age or transcriptional repression2 as well as destabilization 
of the target mRNAs.3 MicroRNA precursors are processed 
by the Drosha RNase III endonuclease and then transported 
from the nucleus to the cytoplasm where they are further 
processed by Dicer-mediated ribonuclease III and by the 
RNA-induced silencing complex.4 Finally, the sense strand 
of the duplex is removed, while the antisense strand directs 
the recognition of the target mRNAs via complementary 
base- pairing interactions. siRNAs are short, 19–21 bp double 
stranded RNAs with two-nucleotide overhangs at both 3′ ends 
generated from double-stranded RNAs by Dicer-mediated 
cleavage.5 Similarly to the microRNA-induced silencing 
process, the duplex associates with RNA-induced silencing 
complex, which in turn catalyzes the specific degradation of 
homologous mRNAs.
In the last 15 years, experimental RNAi has become a 
widespread tool for evaluating loss-of-function phenotypes. 
However, some technological difficulties stalled its universal 
introduction. The most important of these include a large vari-
ation of silencing efficiency of siRNAs synthesized against 
different sites on the same target mRNA6 and the occurrence 
of unintended off-target effects leading to high false positive 
rate.7 In a genome-wide analysis of the efficacy and specific-
ity of silencing of two genes the expression profile was found 
to be siRNA-specific rather than target-specific.8 To improve 
efficiency and reduce off-target effects, a number of empiri-
cal rules,9,10 advanced design tools,11,12 and chemical modi-
fications13 have been reported, all of these help to increase 
the power of specific gene silencing. However, despite the 
guidelines and technological advances in RNAi, it is a matter 
of serious concern that the issues of specificity, noise, and 
heterogeneity remain unaddressed. Pharmaceutical compa-
nies have now abridged interest in pursuing RNAi specific 
treatment strategies.14 Methodological and technical prob-
lems also lead to a significant number of publications with 
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No independent cross-validation of success rate for studies utilizing small interfering RNA (siRNA) for gene silencing has been 
completed before. To assess the influence of experimental parameters like cell line, transfection technique, validation method, 
and type of control, we have to validate these in a large set of studies. We utilized gene chip data published for siRNA experiments 
to assess success rate and to compare methods used in these experiments. We searched NCBI GEO for samples with whole 
transcriptome analysis before and after gene silencing and evaluated the efficiency for the target and off-target genes using the 
array-based expression data. Wilcoxon signed-rank test was used to assess silencing efficacy and Kruskal–Wallis tests and 
Spearman rank correlation were used to evaluate study parameters. All together 1,643 samples representing 429 experiments 
published in 207 studies were evaluated. The fold change (FC) of down-regulation of the target gene was above 0.7 in 18.5% 
and was above 0.5 in 38.7% of experiments. Silencing efficiency was lowest in MCF7 and highest in SW480 cells (FC = 0.59 and 
FC = 0.30, respectively, P = 9.3E−06). Studies utilizing Western blot for validation performed better than those with quantitative 
polymerase chain reaction (qPCR) or microarray (FC = 0.43, FC = 0.47, and FC = 0.55, respectively, P = 2.8E−04). There was no 
correlation between type of control, transfection method, publication year, and silencing efficiency. Although gene silencing 
is a robust feature successfully cross-validated in the majority of experiments, efficiency remained insufficient in a significant 
proportion of studies. Selection of cell line model and validation method had the highest influence on silencing proficiency.
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nonreproducible results in the last few years even in major 
journals.15–18
Gene chips are capable to simultaneously measure the 
expression of almost all human genes. One can use microar-
rays to identify the gene to be silenced19 or to evaluate out-
come of the silencing. In this, by combining a measurement 
before and after RNAi treatment we can identify both target 
and off-target effects at the same time. To date, numerous 
studies utilizing multiple cell lines and various experimental 
technologies employed gene arrays to measure the effect of 
an intended silencing on a transcriptomic scale.
Since many of these experiments have published all the 
raw experimental data, we can mine the gene expression 
pairs to investigate factors affecting RNAi gene silencing 
efficiency. Here, we aimed to process available microarray 
datasets to investigate RNAi silencing efficiency across a 
large number of independent studies and to identify factors 
empowering a successful experiment.
Results
Database setup
Using the GEO search, all together 145,693 samples were 
downloaded. CEL files were available for 134,289 samples 
and of these 28,853 represent a treatment-control pair (Fig-
ure 1a). Reduction to RNAi experiments delivered 1,643 sam-
ples. The total number of pairs (n = 3,160) is higher than the 
actual number of samples as many studies performed repeti-
tions for the silencing and for the control samples as well. In 
the statistical analysis we used each possible pair within one 
dataset. The complete database including all GSM IDs; the 
normalized gene expression table for all JetSet genes20; and 
a table containing descriptive characteristics of the original 
studies including dataset, platform, cell line name, as well 
as treatment options with corresponding control samples are 
available upon request from the authors.
We have evaluated the characteristics of the 207 studies 
included in the analysis (Figure 1b). Only five cell lines were 
utilized in at least 10 independent analyses, these are MCF7, 
A375, HELA, MDA231, and SW480. These five constitute 
47% of all used cell lines, with MCF7 taking the lion’s share 
by 25%. When checking the transfection method, employ-
ment of a transfection reagent was leading with 71.7% over 
a smaller proportion of infection and electroporation, but we 
have to note that a quarter of the studies did not disclosed 
this information. The vast majority used nontargeting RNA 
oligos as negative control treatment. Empty vector (in case of 
infection based transfection), mock (in case of reagent based 
transfection) were both below 5% of the studies while utiliza-
tion of completely untreated cell occurred in only 16 studies.
In respect to our study goals, the most important char-
acteristic is the used method for validation of silencing effi-
ciency. Unfortunately, 13 publications did not disclose the 
used method and 78 studies lacked a relevant publication. 
Among the other studies, the gene-chip and Western-blot 
based techniques were equally popular with one third of all 
studies, and a smaller proportion of 11.4% of all studies used 
quantitative polymerase chain reaction . We have to note that 
some studies measured both mRNA and protein level for the 
same gene—these studies were added to the Western blot 
cohort. Characteristics of the investigated studies are sum-
marized in Figure 1c.
Proportion of significant silencing
We evaluated all investigated genes in each study. This 
approach enables to compare the specificity of the silencing 
against the background noise of nontarget genes. A heat map 
demonstrating the efficacy of gene silencing across all genes 
is presented in Figure 2 and in Supplementary Figure S1. 
Overall, 429 RNAi silencing experiments from the 207 
studies were evaluated (see Supplementary Table S1). The 
down-regulation was below 0.7 in 341 experiments (81.5%) 
and below 0.5 in 257 experiments (61.3%). When evaluat-
ing those with at least two pairs enabling computation of a 
Wilcoxon test, the down-regulation was significant in 131 
experiments. A single pair of measurements was available 
for 60 experiments. The highest significance was achieved 
in two studies using 10 repeated experiments (HNF1B in 
GSE37290: P = 3.9E−18 and CREB1 in GSE12056: P = 
3.8E−17). The average number of silenced samples in the 
nonsignificant cohort with multiple pairs was 1.61 only.
An opposite up-regulation with a fold change (FC) over one 
was observed in 27 experiments, the highest increase was 
7.85. Ranked FC for all genes is presented in Figure 3.
Effect of used methods on silencing efficacy
Since nearly half the samples originated in five cell lines, 
we evaluated the silencing efficiency across all genes within 
these cell lines. Remarkably, the most widely used MCF7 
breast cancer cell line demonstrated the worst response to 
down regulation (mean FC = 0.59 ± 0.06). Best results were 
obtained in the SW480 epithelial colon cancer cell line (FC 
= 0.30 ± 0.16), followed by the MDAMB231 breast cancer 
cell line (FC = 0.35 ± 0.20). We must note that these results 
were delivered in only 10 and 12 silencing experiments, 
respectively. The overall average FC in all other cell lines was 
0.48 ± 0.06 (see Figure 4a).
There was no significant effect on silencing efficiency of 
the used transfection method and of the type of the applied 
control sample (Figure 4b,c). When comparing studies work-
ing on cancer cell lines and those working with other cell lines 
(keratinocytes, airway epithelial, HEK, stem cells, etc., all 
together n = 45 experiments) there was no significant differ-
ence in the achieved silencing power (Figure 4d).
When comparing the methods used to validate silencing, 
Western-blot reached the lowest mean FC (0.43 ± 0.06), fol-
lowed by quantitative polymerase chain reaction methods 
(0.47 ± 0.10) and microarray based validation was performing 
worst (0.55 ± 0.06). The differences between the methods was 
significant by Kruskal–Wallis test (P = 2.8E−04, see Figure 
4e). A summary of the silencing achievements across all stud-
ies for the investigated parameters is presented in Table 1.
Fifty genes were silenced in two independent studies, eight 
genes (ALK, CDK2, CDK4, SRC1, STAT1, MAPK1, HIF1A, 
and EZH2) in three studies, two (ESR1 and MYC) in four, and 
two (TP53 and CTNNB1) in six studies. To compare the effect 
on the same target gene under the different conditions, we 
extracted the achieved FC from the mean FC for these genes 
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using the repeated experiments only. In this analysis, solely the 
used cell line had a significant effect (Figure 4f). Transfection 
method, used control and expression validation methods were 
not significant.
Silencing efficacy and publication
To evaluate the effect of journal prestige on experimental 
success, we compared the achieved P-values to the journal 
impact factors (IF) which was available for 297 experiments. 
The Spearman rank correlation between P-value and IF was 
−0.43 (P = 2.9E−15); and between FC and IF it was −0.15 
(P = 0.003). As our analysis included datasets spanning a 
10-year release range, we evaluated a possible improved 
performance depending on time. When comparing year of 
publication and achieved P-value or FC, the Spearman corre-
lation was not significant (P = 0.16 and P = 0.47, respectively).
Noise and off-target effects
The overall reliability and reproducibility of microarrays has 
been extensively studied previously.21 Here, to evaluate varia-
tions in unaffected genes, we computed the FCs across all 
genes and across all experiments. The median FC in each 
experiment across all genes was 1.002 (range = 0.73–1.28) 
and the median FC in each gene across all experiments was 
1.001 (range = 0.69–1.19). The close position of the median 
values to 1 indicates that there was no systematic distortion of 
the results and that the small variation (also seen in Figure 2) 
is mostly due to noise in the experiments.
Figure 1  Overview of the study and the studies evaluated. Flowchart of the database setup starting with a GEO search and ending up 
having 3,631 siRNA treatment-control pairs (a). The utilized statistical tests (b) start using these pairs. Characteristics of the utilized models 
and techniques across all studies (c).
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In our analysis we normalized the genes across all probe 
sets present in the entire gene chips. In several settings, like 
in case of polymerase chain reaction based validation nor-
malization, a reliable housekeeping gene is required, thus 
selection of a gene minimally affected by the off-target effects 
of RNA silencing is of upmost importance. To identify the 
most reliable housekeeping genes, we computed expres-
sion rate across all 12,209 JetSet best genes present on the 
arrays.20 The proportion of the 419 experiments showing an 
absolute FC below 1.2 are listed for each gene in Supple-
mentary Table S2. The most stable genes are on the top of 
this list while the most unstable genes are at the bottom of the 
list—the top and bottom 10 genes are presented in Table 2.
Discussion
Here, we performed a large-scale validation of the efficiency 
of sequence-specific experimental gene silencing initiated 
by small RNAs homologous to the silenced gene. A major 
advantage of our study is the exclusive utilization of actual 
experimental results (in other words computationally inferred 
effects were left out in the statistical computations). By eval-
uating all together 429 independent experiments with pub-
lished raw gene array data, the overall success rate was 
81.5% while 6% of the studies delivered an opposite out-
come (e.g., increased expression instead of silencing). Mul-
tiple issues influencing silencing power including transfection 
method, the utilized cell line, the type of control, and the vali-
dation method were also assessed.
To effectively activate RNAi and induce gene silenc-
ing, siRNAs must be delivered to the cytoplasm. However, 
the cellular membrane is relatively impermeable to siRNAs 
because of their negative charge and size. Multiple different 
delivery methods are at hand including the use of a cationic 
lipid transfection reagent, increasing cell-membrane perme-
ability with an electrical field in electroporation and the utiliza-
tion of a lentiviral agent to supply the oligos to the target cell. 
Previously, a broad and significant change was observed in 
the transcriptome in response to the transcription reagent.22 
In our study, there was no significant difference between the 
available techniques, even though the lipid-based transfec-
tion reagents reached the numerically lowest efficiency. Inter-
estingly, comparing the deviations across all measurements 
show that the reagent based transfection had the smallest 
confidence interval range compared with the other methods. 
We have to note that in about one-quarter of the studies the 
transfection method was not available at all.
A second critical issue is the use of different cell line mod-
els. Cell lines used in screening and in the validation studies 
do not process the hairpins at the same efficiency. Previously, 
variable hairpin activity in terms of silencing results was 
described in two independent cell lines.23 Only five cell lines 
were used in at least 10 experiments, but these gave almost 
half of all studies—of these, silencing was least significant in 
the MCF7 breast cancer cell line, which accounted for 25% 
Figure 2 Heat map demonstrating gene silencing efficacy across all experiments. Columns include the silenced genes and the rows 
depict the expression for each gene (also ranked according to the order of the columns). Genes and experiments are ranked so that the 
diagonal green line resembles the silencing efficiency of the targeted gene across all comparisons—fluctuations in the remaining area 
correspond to noise and off-target effects of the silencing. Green equals lower expression in the siRNA treated sample compared with control. 
The line is not straight as some genes were silenced in multiple experiments and some experiment contained multiple genes.
Figure 3 Silencing effectiveness across all genes. A ranked order of all silenced genes based on fold change—values below 0 correspond 
to down-regulation, and values over 0 to up-regulation. All together 81.5% of measurements displayed a down-regulation below 0.7 and 30.5% 




Not significant or fold change only
Silenced gene
Down-regulation below 0.7 (81.5%)
Up-regulation
(6.3%)














Cross-validation of RNAi Silencing
Munkácsy et al.
5
of all experiments and most significant in the SW480 colon 
adenocarcinoma cell line. The marked differences between 
the cell lines emphasize the need for multiple model systems 
in order to exclude the possibility of a cell line specific false 
negative result.
Once the experiment is done, one has to verify the reduction 
of gene expression. This can be done on the protein level by 
Western blot, on the mRNA level by quantitative polymerase 
chain reaction for single genes and on the mRNA level for all 
genes together by gene arrays. There are other techniques 
available as well like Northern-blot, sodium dodecyl sulfate 
(SDS)-polyacrylamide gel electrophoresis (PAGE), enzyme-
linked immunosorbent assay (ELISA) or RNA-seq—however, 
only very few studies used these other methods and there-
fore, we could not evaluate their success rate. Of the three 
most common methods, studies using Western blot for vali-
dation achieved the strongest silencing. Our results support 
the current practice in multiple journals requiring Western 
blot validation for studies including siRNA gene silencing.
One could expect more reliable measurement in presti-
gious journals. To evaluate such an effect, we compared the 
achieved P-values to the IF. In this analysis, we found an 
inverse correlation between P-value and IF and between FC 
and IF. These results support the notion that higher ranking 
journals deliver more reliable outcomes. However, we have 
to note that we only included studies having not only multiple 
level of data but also whole transcriptome analysis. To this 
end, the average IF for the journals publishing these more 
complex experiments was 8.51, which is strikingly higher 
than the average IF across all life science journals.
At the same time, there was no correlation between pub-
lication date and silencing efficiency suggesting that current 
techniques are not superior to methods available a decade 
ago.
Many genes are affected by an RNAi experiment and 
only those siRNAs which have decreased off-target effect 
will enable the identification of essential genes in cancer.24 
To assess off-target effect across all genes, we focused on 
spotting the most stable genes, e.g., those having the low-
est proportion of studies with a FC out of the 0.8–1.2 range. 
Conventional housekeeping genes were at the top of this list 
(RPLP0 at #100, GAPDH at #137, and ACTB at #197). How-
ever, some other genes like PSMB4 or RPLP1 have reached 
an even higher rank. When looking at the average expression 
we observed higher variability for genes with a lower aver-
age expression. Our results can guide the selection of highly 
expressed control genes most infallible for off-target effects.
To date, RNAi treatments are not yet established in clini-
cal setting. The first successful phase 1 clinical trial utiliz-
ing siRNA has been completed for macular degeneration 
Figure 4 Correlation between study methods and silencing power. Selection of the cell line model had a marked effect on silencing 
efficiency (a), while utilization of different transfection methods or controls was not significant (b,c). There was no difference between cancer 
and noncancer studies (d). Protocols validating the silencing by Western-blot reached the highest reduction in the gene chip data as well 
(e). When comparing silencing for the same gene within independent experiments (n = 62 genes), only the cell line selection of had a 
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a decade ago.25 However, use of siRNA without a targeted 
delivery vector is only possible for organs with direct access 
like the respiratory system, skin, and the eyes because sys-
temic administration results in swift RNase degradation and 
elimination of the oligos.26 The inability to deliver RNA mol-
ecules to cell populations in vivo roots in their instability, in 
the limited cell uptake and short circulation half-life. Today, 
a wide variety of delivery systems are under development/
optimization to enable site specific delivery of siRNA with 
some already in clinical investigation.27,28 Validation of these 
approaches in a similar study will only be possible once we 
will have access to transcriptomic data generated after in vivo 
siRNA treatments.
In summary, here we took advantage of the significant pro-
portion of studies with available transcriptomic profiles and 
performed a large-scale validation of RNAi gene silencing 
efficiency. Altogether, we can endorse RNAi as a robust fea-
ture successfully cross-validated in most of the experiments. 
However, silencing efficiency was insufficient in nearly one-
fifth of all experiments. Thus, careful study design is neces-
sary including the cautious selection of cell line model and 
validation method as these had the most significant influence 
on silencing proficiency.
Materials and methods
Constructing a database of RNAi experiments. A GEO search 
was made on 1 August 2015 and results were saved into an 
SQL database. NCBI GEO (www.ncbi.nlm.nih.gov/geo/) is 
the largest microarray repository available and the only one 
providing free download of all data. The analysis was per-
formed in the R statistical environment (http://www.r-project.
org). The search was set to include all studies published in the 
last 10 complete years—starting on the 1st of January 2005. 
Then, the GEOsql package was used to perform a text based 
search in the database. In this, the search terms were the 
cell line names in the field’s title, characteristics, source name, 
description of the samples, and title, summary, and overall 
design of the datasets. Cell line names were collected from 
ATCC (http://www.atcc.org), COSMIC (http://cancer.sanger.
ac.uk/cosmic) and the Cancer Cell Line Encyclopedia (http://
atlasgeneticsoncology.org/cell_lines.html). The search was 
performed using the “like” command to enable identification of 
dissimilar nomenclature (e.g., “MCF7” or “MCF-7” or “MCF 7”).
In the second step, each of the identified experiments was 
assessed manually to identify those with an RNAi study. To 
be included in the final database, the study design had to 
fulfill two main criteria: (i) there is at least one control sample 
for each experiment, (ii) only one treatment is administered in 
the treatment-control pair.
We have excluded studies focusing solely on drug treat-
ment, hyper- or hypothermia, radiation, viral, and bacterial 
infection. Also, studies performing the experiments at dif-
ferent passage number were excluded. In this sense, stud-
ies with long-term treatment (e.g., over 2 weeks), studies 
in Matrigel or polyamide gels, utilization of cell lines with an 
evolutional selection were included in the study as long as 
the requirement for an untreated control-treated pair was ful-
filled. A study was also included in case the silencing was 
performed against a mutated form of the gene.
Description of the methods was not unambiguous in the 
overwhelming majority of the studies. To enable a reliable 
analysis, each sample in entire database was processed by 
three independent team members (Z.P. or N.S., and B.B.) and 
the final database was set up by assessing the concordance 
of these. In case there was discordance in the interpretation, 
the original study was also read by a third team member 
(G.M.) and the final designation was set up by selecting the 
concordant interpretation of at least three investigators.
Processing of gene microarrays. First, all gene chips were 
downloaded and normalized using MAS5 in the R-statistical 
environment. We have selected MAS5, because it performed 
among the best normalization methods when compared with 
reverse-transcription polymerase chain reaction validated gene 
expression results in our previous study.29 Then, the qual-
ity of each gene chip was assessed to check all parameters 







Cell line A375 47 0.40 0.02 9.3E−06
HELA 22 0.42 0.05
MCF7 101 0.60 0.03
SW480 10 0.30 0.07
MDA231 12 0.35 0.09
Other 237 0.47 0.03
Transfection Reagent 221 0.50 0.02 n.s.
Electroporation 17 0.47 0.08
Infection 70 0.47 0.04
NA 121 0.45 0.04
Control Empty vector 11 0.39 0.10 n.s.
Mock 15 0.41 0.08
Nontargeting RNA 346 0.50 0.02
Untreated cells 16 0.50 0.09
NA 41 0.40 0.05
Validation Microarray 137 0.55 0.03 2.8E−04
qPCR 47 0.47 0.05
Western blot 136 0.43 0.03
NA 109 0.46 0.04
Study Cancer 384 0.48 0.02 n.s.
Noncancer 45 0.47 0.07
NA, not applicable; n.s., not significant; qPCR, quantitative polymerase chain 
reaction.
Table 2 Top 10 most stable genes (highest proportion unchanged) and top 
10 most unreliable genes (lowest proportion unchanged) are listed
Most reliable genes Stable %
Most unreliable 
genes Stable %
OAZ1 96.04 GH2 11.66
RPL39 94.17 PPP1R3A 11.66
PSMB4 94.17 CRTAM 11.66
RPL27 93.71 SLC26A3 11.66
MATR3 93.47 PRSS1 11.19
RPS7 93.47 PDE6C 10.96
EEF1A1 93.24 CLCA3P 10.96
RPL35 93.24 MSTN 10.26
CALM2 93.01 G6PC 9.79
PSMB1 93.01 CD1E 9.56
To assess off-target effects, the proportion of studies delivering a fold change 
between 0.8 and 1.2 was calculated for each gene across all studies.
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suggested in the Affymetrix white paper (http://www. affymetrix.
com/support/technical/whitepapers.affx). In this, we have 
evaluated the following parameters: percentage present calls, 
background, noise, spike-in controls, and RNA degradation as 
described previously.30
Processing of RNAi experiments. In each experiment, the 
silenced and the corresponding control experiments were 
paired. Within each study, the repetitions were treated as 
sovereign pairs, and every treatment replica was compared 
with all available controls. To assess the magnitude of the 
silencing, we computed mean FC across all possible pairs 
for each gene in each experiment. Finally, Wilcoxon signed-
rank test was performed to statistically validate the silencing 
effect. In case there were no repetitions available, then the 
FC of expression alteration was computed only.
Statistical analyses. Dichotomous variables were compared 
with the RNAi silencing efficiency using Wilcoxon test. Multiple 
groups including method of validation, utilized cell line, transfec-
tion method, and type of control samples were compared using 
Kruskal–Wallis test. Continuous variables including impact fac-
tor and year of publication were compared using Spearman 
rank correlation. Statistical significance was set at P < 0.05.
Off-target effects. To identify genes most infallible for off-tar-
get regulation (e.g., housekeeping genes) and genes most 
fallible to show altered expression after RNAi treatments, 
we calculated the FCs and the false discovery rates across 
all genes in all experiments. Genes which are expected to 
change their expression in relation to the given RNAi treat-
ment identified by using the Pathway Commons database31 
were excluded from this analysis. Finally, the proportion of all 
experiments showing an absolute FC between 0.8 and 1.2 
and a false discovery rate <5% was computed.
Supplementary material
Figure S1. The heat map of Figure 2 at full resolution.
Table S1. Results of the Wilcoxon test for each gene in each 
study separately.
Table S2. Gene ranking for stability against off-target effects 
for all genes.
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